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Abstract:
Studies have shown that pharmaceuticals and other personal care products (PPCPs) are
present in the environment, especially in water, due to different human activities. Some
of these compounds are toxic to our eco-system. Although there is no evidence of adverse
human health effect from the presence of PPCPs in the environment to date , some
adverse effects on aquatic life cycle already have been found. Therefore, protecting our
environment as well as human health from adverse effect(s) of PPCPs is a growing
concern.

The objective of this thesis work was to collect information about the principal
approaches available to pharmaceutical industries for reducing the introduction of PPCPs
to the environment and to identify and address any divergence or disagreement about the
effectiveness of these approaches to address this issue. Through the use of literature
review, case studies, and in-depth interviews where necessary, consistent information has
been consolidated and discrepancies have been resolved to the extent possible and this
reference document has been created for the purpose of fostering the awareness about this
issue and about the possible ways to minimize the problem from pharmaceutical industry
perspective.
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Introduction:
Presence of pharmaceuticals and other personal care products in the environment is one
of the most serious concerns today. There are different classes of chemicals recognized as
continuing or emerging sources of contaminant that are continuously released to
environment, mainly through different human activities. These classes include a wide
variety of compounds used in industry and in home, for example, surfactants,
disinfectants, solvents, etc. and those that constitute prescription and nonprescription
drugs like antibiotics, antacids, antimicrobials, etc. Besides these, sex and steroidal
hormones are also being recognized as emerging contaminants of environment. All these
compounds have high usage rates and also have potential health effects and some
undesirable effects on non-target organisms, including endocrine disruption and
development of antibiotic resistance or toxicity (Lee, Zaugg, Cahill, and Furlong, 2000,
58).

The common sources of PPCPs in the environment are pharmaceutical
wastewater, human excreta and disposal of unused prescription and non-prescription
drugs. It is believed that concentrations of different chemicals in wastewater from
pharmaceutical industries are negligible, in respect of producing any adverse effect on
living creatures. But, still the concentrations of some of these chemicals are of a great
concern as many of these chemical compounds have cumulative properties and after a
couple of years, when these chemical compounds reach their MEC 1 (Minimum Effective

1

MEC is the minimum amount of any chemical compound, in body’s circulatory system, required to
produce any effect of that chemical within the body.
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Concentration) in the environment, they produce adverse effects to living creatures to
some extents.

Proper disposal of unused prescription 2 and non-prescription drugs is also
important because most of the pharmaceuticals and personal care products get
accumulated after disposal in the environment due to their resistant nature to biological
degradation process and sometimes their adverse effects on non-target receptors 3 can not
be identified, even unpredictable, due to their low concentration applications. As for
example, reproductive hormones like estrogen which is used for birth control in human
also interfere with reproduction and development stages in reptiles. This estrogen
hormone also results in widespread sexual disruption in male fishes. Similarly, some
antidepressant pharmaceuticals like serotonin reuptake inhibitors inhibit growth rate in
frogs and fishes. Sometimes, exposure to these accumulated PPCPs result in the
development of drug resistant pathogenic organism 4 in the environment. As for example,
over use of antibiotics today, results in higher concentration of antibiotics residue in
wastewater this in turn results in the creation of antibiotic resistant bacteria. Since, all
these drug residues are present in very low concentration; it is difficult to identify their
immediate adverse effect and combined effects of multiple PPCPs, the persistence and
bioaccumulation of these compounds, and long term multi-generational effects 5 are also
difficult to predict. (Viadero. 2000,1)

2

Prescription is a physicians order for the preparation and administration of a drug or device for a patient.
Receptor - a structure on the surface of a cell (or inside a cell) that selectively receives and binds a
specific substance.
4
Disease producing microorganism
5
Information on the long-term health effects of low-level, long-term exposures of drug substances is
particularly limited.
3
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However, different approaches like product stewardship, end-of-pipe treatment
technologies etc. are being currently used to prevent the introduction of PPCPs into the
environment.

Background (Preliminary) Literature Review:
“Human exposure to environmental concentrations of pharmaceuticals 6 is
believed to be primarily through ingestion of drinking water and, for compounds
that bio-accumulate, through ingestion of meat or fish” (Hagan 2000, 66).

When pharmaceuticals and personal care products 7 (PPCP) are present in very
low concentrations in surface or groundwater, which is a source of drinking water, the
most serious concern associated with their presence is not necessarily immediate acute
effects on human health, but rather with the effects that can accumulate over a long
6

Pharmaceuticals are substances that are aimed to cure, prevent, or recognize diseases and relieve pains
through their application in the organism.
7
PPCP includes cosmetics, fragrances, skin care products, nutritional supplements, and over-the-counter
medications.
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period of time to produce truly distinguishable changes (Daughton & Ternes, 1999).
Sometimes, it becomes difficult to identify any of these changes in certain non-target
populations as they take a long period of time to occur. Current comprehensive
environmental risk assessments and epidemiologic studies8 lack consideration of this
type of long-term effects (Drewes, Heberer and Reddersen, 2002, 269).

Sometimes, water characteristics get changed according to its use by humans. We
use a variety of chemicals everyday for different purpose like for industrial purpose or for
domestic purpose. After use, a portion of these chemicals find their way to either
industrial wastewaters or domestic sewage. We are able to remove some of these
chemicals through different treatment methods. After treatment, this wastewater is
discharged to a receiving stream or water body. At any point of downstream flow of
water, user receives the water and chemicals from all upstream users and this process
goes to continue throughout the downstream of water flow. In this way, some chemicals
are destroyed by means of some physical, chemical or biological treatment methods and
those which remain unaffected, ultimately reaching a final receiver, e.g. oceans where
they are precipitated due to evaporation of water and are accumulated (Hagan. 2000, 64).

In some closed watersheds 9 , e.g., the Great Salt Lake, the final receptor is a lake
and/or wetland. Planned reuse of treated wastewater is important in water-short

8

Epidemiologic Studies - Studies designed to examine associations—commonly, hypothesized causal
relations. They are usually concerned with identifying or measuring the effects of risk factors or exposures.
The common types of epidemiologic studies are case-control studies, cohort studies, and cross-sectional
studies.
9
A watershed (also called a drainage basin or a catchment area) is defined as an area of land that intercepts
and drains precipitation through a particular river system or group of river systems. In other words it is a
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areas of the US and many other countries where water resources are limited
relative to need. Planned reuse can be divided into two categories:
(1) use that does not involve human consumption of the water such as
irrigation of golf courses and landscaping; and
(2) uses that result in human exposure, including drinking water supply.
Planned reuse is currently always indirect rather than direct (i.e., using treated
sewage effluent as drinking water supply influent). Indirect reuse includes
recharging an aquifer used for a ground water supply with treated effluent and
discharging treated effluent to a water supply reservoir (Hagan 2000, 64).
Advanced sewage treatment methods like activated carbon adsorption and membrane
filtration in conjunction with planned water reuse is always much more rigorous than that
used for discharges to surface waters (Hagan 2000, 64).

The contaminants enter the environment by means of different transport pathways
such as, on one hand, through direct disposal in sewage systems and landfills, and on the
other hand, as runoff or infiltration from fields following application of wastewater
treatment sludge or animal manure (Lee, Zaugg, Cahill, and Furlong, 2000, 58). The
main route by which pharmaceuticals enter the environment is via water discharges, as
most of the pharmaceuticals found in the environment have been proved water-soluble.

region of interconnected rivers and streams which functions as a unified system for water transport.
Watersheds may be of various forms: a closed watershed empties into an inland body of water, whereas an
open watershed drains to the ocean.
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Among the different routes into the environment, the therapeutic use 10 of
pharmaceuticals and the subsequent excretion of the active ingredients or their
metabolites in urine and feces, quantitatively constitutes the most important one.

When applying pharmaceuticals to humans, many of these compounds are
excreted with only slight transformations or even unchanged and often conjugated
to polar molecules (e.g. as glucoronides). Due to an incomplete elimination of a
number of pharmaceuticals used in human medical care in sewage treatment
plants several classes of drugs are found in sewage effluent. Among these classes
are antirheumatics (e.g. Diclofenac), analgesics (e.g. Propyphenazone) as well as
the above mentioned blood lipid regulators (e.g. Clofibric acid). High
concentrations of sewage contaminants may be expected in the receiving surface
waters with regard to the high contribution of sewage treatment work’s effluents,
especially in areas with a high population density (Scheytt, Leidig, Marsmann and
Heberer 2000, 253). The chemicals which are excreted by human beings, first
enter into sewage treatment systems and then enter into surface water and
groundwater when the treated wastes are discharged (Hagan. 2000, 64).

Although it has been cited in some literature that neither manufacturing of
pharmaceuticals nor disposal of sewage sludge on land constitute a major source of
pharmaceuticals in the environment, still manufacturing, wastewater and waste from

10

Therapeutic use means use for the purpose of preventing, diagnosing, curing or alleviating a disease,
ailment, defect or injury in persons; or influencing, inhibiting or modifying a physiological process in
persons; or testing the susceptibility of persons to a disease or ailment.
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pharmaceutical industries are considered to be important sources. The pathways of
contamination from disposal of sewage sludge would be to surface water by runoff that
contacted the sludge or to ground water by precipitation that percolates through the
sludge into an underlying aquifer (Hagan 2000, 64). Sewage Treatment plant effluent has
been recognized a source of certain natural chemicals like human estrogen, caffeine etc.,
in the aquatic environment.

In order to determine the right approach to address this issue, it is first necessary
to identify what types of pharmaceuticals are normally found in the environment. But,
unfortunately, still there is no single analytical method to detect all pharmaceuticals.
Very sophisticated analytical research methods with very low detection limits and highest
accuracy are necessary to detect most of the pharmaceuticals in the environment at very
low concentrations. Such testing can only be done by using special analytical equipment
which is only available in certain analytical research laboratories, or certain commercial
laboratories that also specialize in methods research (Pontius. 2002, 9).

Information about the treatment methods of pharmaceutical compounds is not
very common in the public literature. However, granular activated carbon, powdered
activated carbon, nano-filtration and reverse osmosis are the most common methods used
to remove synthetic organic pharmaceuticals compounds from water. Flocculation 11 with
ferric chloride and slow-sand filtration had proven ineffective as treatment processes to
remove low levels of pharmaceuticals found in drinking-water where a combination of

11

Flocculation - The agglomeration of finely divided suspended solids into larger, usually gelatinous,
particles.
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ozonation and filtration with or without granular activated charcoal has been proven as a
very important treatment (Pontius, 2002, 8).

Again, in order to eliminate pharmaceuticals completely from wastewater and
sewage sludge, it is assumed that an advanced treatment technology, like reverse
osmosis, may be very effective. Research is going on to determine the most effective
wastewater treatment method.

USEPA has not set a national primary drinking water regulation
(NPDWR) for PPCPs. USEPA believes there is not sufficient information to
warrant regulation of PPCPs at this time. (USEPA 2002b) Other countries are
considering how pharmaceuticals might be regulated. (Lange and Dietrich 2002)
Under the National Environmental Policy Act of 1969, the U.S. Food and
Drug Administration (FDA) requires Environmental Assessments on the impact
of individual pharmaceuticals on the environment. (Daughton and Ternes 1999)
USEPA does not require routine monitoring for PPCPs at this time. USEPA has
not included contaminants on the Drinking Water Contaminant Candidate List
(DWCCL) solely on the possibility of their endocrine disruption potential. But,
USEPA may add certain representative PPCPs to the DWCCL and Unregulated
Contaminants Monitoring Rule (UCMR) in the future. (USEPA 2002b) (Pontius.
2002, 8)
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Although, there is no drinking water regulation or routine monitoring requirement
for PPCPs has been set by USEPA till-to-date because of the unavailability of enough
information needed to justify regulating PPCPs in drinking water but, now-a-days federal
regulators and scientists are becoming more and more concerned about the issues of
emerging contaminants i.e. PPCPs and continue to include and evaluate PPCPs in
contaminant selection process and carrying out research efforts to determine whether
regulation is necessary or not (Grumbles. 2006). USEPA might reconsider drinking water
regulations for all of these contaminants in near future.

Today, many companies are using a cradle-to-cradle stewardship 12 concept to
address this issue. According to this concept, companies are taking many actions like
altered drug design and packaging system for drugs, modified drug delivery pattern,
improved drug dispensing methods, more effective methods of drug disposal, etc. in
order to reduce the risk from introduction of pharmaceuticals into the environment.
Manufacturing facilities are making every effort to assure that product is not lost to the
waste stream. Manufacturing releases would be localized and likely a minor contributor
to the environment. Some of these ideas for minimizing the release of PPCPs to the
environment have already been put forth (Daughton and Ternes 1999). As per Daughton,
“For true cradle-to-cradle stewardship of PPCPs, a holistic integration of all
aspects of the production-consumption cycle is required – one that takes into
consideration the needs and costs of the complete cycle from drug
discovery/design to distribution, end use, and disposal/recycling.”

12

Cradle-to-cradle stewardship means extended product responsibilities.
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In one study regarding the avenues towards “Green Pharmacy” by Christian G.
Daughton, he recommended some methods for disposal of PPCPs by the end user i.e.
disposal of drugs to domestic sewage systems is probably the least desirable way to
dispose of any drug while the two better alternatives might include pharmacy take back
program as a part of cradle-to-cradle stewardship and disposal in household trash
destined for engineered landfills (still not desirable) to address the issue of PPCPs in
environment.

Methodology:
I.Literature Review:
For the purpose of this thesis work, a literature review has been conducted to collect
information from the U.S. and Western Europe. That means literature published in these
geographical areas have been reviewed as it is believed by the researcher that most
advanced technologies are being practiced in the U.S. and Western Europe.
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Literature published in English, from 1985 through the present have only been considered
for review as it is assumed by the researcher that the technologies used before 1985, are
mostly outdated now, particularly in these geographical area and bear no relevance with
purpose of this thesis work.

Articles from professional journals, books by acknowledged experts, papers published on
the WebPages of academic institutions and professional organizations and official
documents posted on WebPages of governmental agencies and corporations have been
considered as an appropriate sources for review while writings from, supported by, or
posted on the WebPages of: advertising or marketing groups, advocacy organizations, or
organizations with vested interests in one outcome or another have been considered
inappropriate sources of information for this thesis work.

The literature review has been conducted thus to find out information to answer the
following questions:
•

What are the approaches available to address the issue of PPCPs?

•

How effective are these approaches are to address this issue?

•

What are their limitations?

•

Is there any disagreement or discrepancy about the effectiveness of these
approaches to address this issue?

•

Which one is the best approach (most effective) from all aspects?

•

Is there any possibility of improving the effectiveness of these approaches?
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•

What new approaches, companies are planning to take in future to address the
issue of PPCPs?

For the purpose of this thesis work, only manufacturing process stage in
pharmaceutical industries has been considered as the potential source of contaminant to
pharmaceutical wastewater and other stages of pharmaceuticals and other personal care
products manufacturing like packaging etc. have been excluded from the list of potential
sources of contaminant to wastewater.

II. Case Studies
Information has been collected, through case studies, about the view of pharmaceutical
industries regarding the issue of pharmaceuticals and other personal care products in
environment. Case study approach has been considered as an appropriate methodology
for this work to answer ‘What’, ‘Why’, ‘How’ – types of questions, over which little or
no control could be exerted, as there was no scope of any hand-on laboratory work during
the course of this thesis work.

For the purpose of case study, Websites of 10 leading pharmaceutical companies
have been visited to find out specific information about their current approaches towards
this issue and their future plan (if any) towards this issue. These 10 pharmaceutical
companies have been selected for case study purpose based upon the availability of
information, in their respective websites, required for this thesis work. Case studies have
been performed by reviewing their electronic copies of annual report (s), EHS
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performances, corporate responsibilities, and newsroom as it is believed that companies,
in general, put their most recent environmental health and safety information in all or any
one of these mentioned areas. Specifically, the following information has been looked for
during case studies:
•

What current approaches are being taking?

•

How these approaches are being applied?

•

Why any company has chosen any particular approach?

•

What will be their next plan to address this issue?

III. In-Depth Interviews
For the purpose of this paper, in-depth interview processes with pharmaceutical company
personnel have been conducted to verify the reliability of the information collected
through literature survey and case study and to collect additional information about their
specific approaches. Both EHS personnel as well as production personnel of
pharmaceutical companies have been interviewed as it has been believed that these
personnel keep the most updated EHS information of the respective companies and about
their future EHS goal (s). Specifically, the following information has been looked for
during this interview stage:
•

What are the most recent approaches from company’s perspective to address this
issue?

•

Why they have chosen these particular approaches?

•

Why they are not using any other approaches?

•

What they are thinking to do in near future regarding this issue?

19

•

Are they doing so actually to protect our environment, or just due to some
regulatory concern to look the company doing better?

IV.Analysis
Information about the past and present approaches of pharmaceutical companies towards
the issues of PPCPs that collected through literature review, have been verified with that
collected through case studies and finally, validated against the information collected
through interview stage and the final conclusion has been drawn based on these validated
information.

Findings
I. Literature Review
Generally, five types of manufacturing processes are common in pharmaceutical
industries. These are research, fermentation 13 , biological or natural extraction 14 , chemical

13

Fermentation - The process of growing microorganisms to produce chemicals or pharmaceutical
compounds. Microorganisms are usually grown under controlled condition in large tanks called fermentors.
14
Extraction - the process of obtaining something from a mixture or compound by chemical or physical or
mechanical means.
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synthesis and finally, mixing-compounding-formulating. Many pharmaceutical industries
use any one of these five manufacturing processes while the others use a combination of
two or more manufacturing processes in their regular practice. (The research type of
manufacturing process has not been considered as a potential source of contaminant to
wastewater for this thesis work as the volume of wastewater that produces everyday from
a research process is negligible as compared to that of the other four types of
manufacturing processes and therefore, has not been discussed further in this paper.)

Examples of different classes of pharmaceutical products, manufactured by using
the above four processes, are given in the following table:

Table 1
Type of Process
Fermentation

Example of Pharmaceutical Products
Antibiotics – Chlortetracycline, Penicillin G, Penicillin V,
Streptomycin; Therapeutic Nutrients; Vitamins - Ascorbic
acid (C), Riboflavin (B2); Steroids etc.

Biological or natural

Enzymes and Digestive Aids; Central Depressants –

extraction

Codeine, Morphine Sulfate; Hematological Agents –
Heparin; Insulin etc.

Chemical Synthesis

Antibiotics – Clindamycin; Cardiovascular Agents –
Methyldopa; Central Stimulants – Amitriptyline, Caffeine;
Central Depressants – Acetaminophen, Aspirin; Hormones Cortisone acetate, Dexamethasone acetate, Hydrocortisone,
Testosterone; Vitamins – Niacinamide etc.

Mixing, compounding or

Mouthwash – Listerine; Powders; Tablets and Capsules;

formulating

Ointments – Caladryl, Vicks Vaporrub etc.
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From a portfolio survey by EPA, it can be said that the number of pharmaceutical
industry using the fermentation method is increasing since 1990 (USEPA Technical
Development Document. 1998, 3-40). As per the survey report, this number has been
increased by 100% since before 1990, while the use biological or natural extraction
method has decreased by 15% and the other two methods have remained point as before.
These manufacturing processes are being used in pharmaceutical industries, either in
batch operation or in continuous operation or in a combination of both. Therefore,
wastewater characteristics from different manufacturing facilities are not unique and vary
according to the manufacturing process type.

Fermentation process is very important in antibiotics and steroid manufacturing
units. Fermentation is carried out as a large-scale batch operation. Therefore, before
charging a new batch, water wash and sterilization of the fermenter vessel is a
compulsory step to prevent cross contamination and phase infection. This wastewater
from the fermenter vessel, spill cleanup water, wastewater that is generated from product
recovery stage and that from liquid scrubber (often is used to clean fermentation wasteoff gas before discharging it to air), along with spent broth and infested batch (if any),
constitute the waste stream of a fermentation unit.

Biological or natural extraction is one of the most important process in
pharmaceutical manufacturing because by this method, most of the natural active
ingredients of medicinal and other personal care products are extracted from natural
resources like plant, fungus etc. These active ingredients fall into different categories like

22

alkaloids, glycosides, tannins, resins, volatile oils etc. Different portion of plants are
being used for these extraction processes, e.g., Senna leaves are used to extract sennoside
alkaloid which is used as an active ingredient in laxative and purgative preparations;
similarly, digitalis leaves are used to extracts dioxin and digitoxin glycosides which are
active ingredients in many cardiac medicinal preparations like those are used in cardiac
arrhythmia 15 etc; similarly, clove oil is used as dental analgesic, antiseptic preparation
etc. . Many of the natural volatile oils, extracted by this method, are used as flavoring
agents in different cosmetics preparations like, soaps, body spray, cream etc. Therefore,
biological or natural extraction processes are very much essential in pharmaceutical and
other personal care products manufacturing.

In this extractive process, the active ingredient(s) is (are) extracted with a solvent
or with a mixture of solvents, depending on the specific type of active ingredient(s)
through a series of batch operations. This equipment wash water, spent raw material like
plant residue, chemical waste like spent solvent, spill cleanup water etc. are considered
the major sources of waste in the effluent of a extraction unit. The waste load in the
effluent is normally very high because natural active ingredients are present in a very
minute quantity in the plant or animal sources. Solid wastes constitute the major portion
of this waste load.

Chemical synthesis is another important method of pharmaceutical manufacturing
and is now being widely used in the industry to manufacture medicinal and other
15

Cardiac Arrhythmia - Irregularity of the heartbeat caused by damage to or defects in the heart tissue and
its electrical system. An unusually fast rhythm (more than 100 beats per minute) is called tachycardia. An
unusually slow rhythm (fewer than 60 beats per minute) is called bradycardia.

23

cosmetic products where the biological method is not economically feasible and the
required ingredients can be manufactured in a chemical set up, using a number of organic
and/or inorganic chemical reactions. This is a batch operating process.

In chemical synthesis, the same equipment is used for different product
manufacturing and the wastes characteristics vary accordingly. The equipment wash
water, process waste like spent solvents, precipitates, reaction by-products etc., spill
cleanup water, wet scrubber water etc. are the major sources of contaminant of the
wastewater effluent from a chemical synthesis unit.

Active ingredients are converted into different dosage form like tablet, capsule,
liquid preparations etc. by the mixing, compounding or formulating processes. These
dosage forms are the final usable forms. The equipment wash water, floor wash water,
water from wet scrubber and spill cleanup water are the major sources of wastewater in a
mixing, compounding or formulating unit.

Therefore, all types of pharmaceutical manufacturing industry generate
wastewater containing a variety of pollutants. Generally, three types of pollutants are
presents in pharmaceutical wastewater. These are conventional pollutants, priority
pollutants and non-conventional pollutants. The following table represents a general list
of these three category pollutants which may be presents in pharmaceutical wastewater:
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Table 2
Pollutants
Conventional
Pollutants

Examples
BOD5, Oil & Grease, pH, Fecal Coliform, TSS

Acetaldehyde, Acetic acid, Acetone, Acetonitrile, Acetophenone, Allyl
chloride, 4-Aminobiphenyl, Ammonia, n-Amyl acetate
Amyl alcohol, Aniline, Benzaldehyde, Benzotrichloride, Benzyl
alcohol, Benzyl chloride, Benzyl bromide, Biphenyl,
Bis(chloromethyl)ether, 2-Bromo-Propanoylbromide, 2-Butanone
(MEK), n-Butyl acetate, n-Butyl alcohol, tert-Butyl alcohol, sec-Butyl
alcohol, n-Butylamine, Carbon disulfide, Catechol, Chloroacetic acid
2-Chloroacetophenone, 3-Chloro-4-Fluoroaniline, Chloromethyl
methyl ether, COD, Cresol (Mixed), Cumene, Cyclohexane,
Cyclohexanone, Cyclopentanone, Cyclohexylamine,
1,2-Dibromoethane, 1,2-trans-Dichloroethene, Diethylaniline,
Diethyl ether, Diethylamine, Diethyl carbonate, Diethyl-ortho formate
Dimethylamine, 1,1-Dimethylhydrazine, N,N-Dimethylacetamide
N,N-Dimethylformamide, N,N-Dimethylaniline, Dimethylcarbamyl
Non
conventional chloride, Dimethyl sulfoxide, 1,4-Dioxane, N-Dipropylamine,
Epichlorohydrin, Ethanol, Ethylene oxide, Ethylamine, Ethyl bromide
Pollutants
Ethyl cellosolve, Ethyl acetate, Ethylene glycol, Ethyl cyanide,
Formaldehyde, Formamide, Formic acid, Furfural, Glycol ethers, nHeptane, 2-Hexanone, n-Hexane, Hydrazine, Iodoethane,
Iodomethane, Isobutyraldehyde, Isopropyl ether, Isopropanol,
Isopropyl acetate, Isobutyl alcohol, Methanol, Methyl cellosolve
Methyl amine, Methyl formate, 2-Methyl pyridine, 2-Methoxyaniline,
Methyl methacrylate, Methyl-t-butyl-ether, Methylal, Methyl isobutyl
ketone (MIBK), N-Nitrosomorpholine, n-Octane, n-Pentane,
Petroleum naphtha, Polethylene glycol 600, 1,3-Propane sulfone
n-Propanol, B-Propiolactone, Propionaldehyde, 1,2-Propyleneimine
Propylene oxide, Pyridine, Styrene, Tetrachloroethene,
Tetrahydrofuran, Trichlorofluoromethane, 2,4,5-Trichlorophenol,
Triethylamine, Vinyl acetate, Xylenes
Acrolein, Acrylonitrile, Benzene, Benzidine, Bromoform,
Bromomethane, Chlorobenzene, Chloroethane, Chloroform,
Chloromethane, Cyanide, 1,1-Dichloroethane, 1,2-Dichloroethane
1,1-Dichloroethene, 1,2-Dichloropropane, Ethylbenzene,
Priority
Hexachlorocyclopentadiene, Hexachloroethane, Methylene chloride
Pollutants
Nitrobenzene, 2-Nitrophenol, 4-Nitrophenol, o-Dichlorobenzene
p-Dichlorobenzene, Phenol, 1,1,2,2-Tetrachloroethane,
Tetrachloromethane, Toluene, 1,1,1-Trichloroethane,
Trichloroethylene, 1,1,2-Trichloroethane, Vinyl chloride.
(Source: USEPA Technical Development Document. 1998, Table 6-1, 6-12)
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Wastewater is characterized in terms of its BOD5 16 , COD 17 , TSS content, flow
rate and pH. These characteristics of wastewater from different pharmaceutical industries
vary according to the specific type of manufacturing process. The following table
represents a general comparison of the characteristics of wastewaters from four different
types of manufacturing process units, assuming that each unit uses only one type of
process.
Table 3
Type
BOD5
COD
TSS
Flow Rate
of Process
Fermentation
High
High
High
Large
Biological or Natural
Low
Low
Low
Small
Extraction
Chemical Synthesis
High
High
High
Large
Mixing, Compounding
Low
Low
Low
Small
or Formulating
(Source: USEPA Technical Development Document. 1998, 3-29:38)

pH
4.0 – 8.0
6.0 – 8.0
1.0 – 11.0
6.0 – 8.0

But, in actual practice, each pharmaceutical industry uses a combination of two or more
of the above four processes. Therefore, the characteristics of wastewater vary from
industry to industry, depending on the types of processes in use.

Pharmaceutical industries discharge these wastewaters to the water of United
States either directly or indirectly through publicly owned treatment works (POTWs). It
is generally believed that concentrations of different chemicals in wastewater from the
pharmaceutical industries are negligible, with respect to the potential of producing any
adverse effect on living creatures. However, recent studies have shown that although

16

BOD5 - Biochemical Oxygen Demand is a biological laboratory procedure that measures the rate of
oxygen use while stabilizing decomposable organic mater under controlled conditions of time (5 days) and
temperature (20ºC).
17
COD (Chemical oxygen demand) - the amount of oxygen in mg/l required to oxidize both organic and
oxidizable inorganic compounds.
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these chemicals are present in a minute quantity, some of them produce adverse effects
on aquatic life due to their cumulative effects. To address this issue, besides onsite
wastewater treatment technologies, pharmaceutical industries are using product
stewardship technology. The following table represents the common trends in treatment
technologies used at pharmaceutical industries before 1990 and after 1990 onwards on a
percentage basis;
Table 4
Percentage of facilities
Percentage of facilities
using this type of
using this type of
Treatment Technology
treatment technology
treatment technology in
Prior to 1990
1990 Onward
Neutralization
26.0
44.3
Equalization
20.1
28.6
Activated sludge
16.9
20.5
Settleable solids removal
13.3
NA
Primary sedimentation
12.0
NA
Aerated lagoon
7.5
4.9
Primary clarification
3.9
9.8
Chlorination
3.6
2.5
Polishing ponds
3.2
NA
Waste stabilization pond
2.9
2.5
Trickling filter
2.9
2.0
Multimedia filtration
2.3
6.1
Steam stripping
1.9
5.7
Evaporation
1.9
NA
Secondary clarification
1.6
20.9
Granular activated carbon
1.3
3.3
Oxidation
1.0
2.0
Dissolved air flotation
1.0
NA
pH adjustment
NA
50.0
Phase separation
NA
12.3
(Source: USEPA TDD. 1998, Table 3-9, 3-53) NA – Not Available from Survey data.
The total of the percentage in both the columns is not equal to 100 because some
industries use more than one treatment technologies while some industries do not operate
any onsite treatment unit.
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The major onsite wastewater treatment technologies (USEPA Technical Development
Document. 1998, 7-1) are as follows:
1. pH adjustment or neutralization
2. Equalization
3. Advanced biological treatment
4. Cyanide destruction
5. Multi-media or Multi-layer filtration
6. Polishing pond treatment
7. Steam stripping and steam stripping with rectification
8. Granular activated carbon adsorption
9. Air stripping
10. Incineration

1. pH Adjustment/Neutralization:
Effectiveness of most of the pharmaceutical wastewater treatment technologies depend
on the pH of the wastewater stream and these treatment technologies work best at a
certain specific pH range. Therefore, pH adjustment or neutralization is usually done
prior to many wastewater treatment operations. In any type of sedimentation process, pH
adjustment or neutralization is important because solubility of most of the constituents in
pharmaceutical wastewater is pH dependent. pH adjustment units usually consist of a
mixing tank, stirring equipment and feed system for chemicals. pH is adjusted in the
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mixing tank by adding either acids or alkali, depending on the desired pH. The pH of
final discharge is usually adjusted to between 6 and 8.5. (Guyer, H. 1998; 103)
Advantage:
•

pH adjustment is used as a pretreatment technology, prior to many physical,
chemical and biological wastewater treatment processes to improve their
effectiveness.

•

pH adjustment is very much important for maintaining structural integrity of the
membrane in filtration unit.

•

pH adjustment is also useful in reducing total solid content of wastewater stream
through precipitation of many compounds whose solubility is pH dependent.

Limitation:
•

This is a chemical addition process. Therefore, this process increases total
chemical load of the wastewater.

•

Some of the pH adjusting compounds (like NaOH) are expensive.

2. Equalization:
In any particular production day in a pharmaceutical industry, wastewater flow rate from
different production units will vary according to the speed of the processes and thereby,
sometimes overload and affect the performance of different wastewater treatment units.
For example, biological and chemical treatment units work best at a constant inlet
wastewater flow rate because it guarantees adequate process retention time. Similarly in
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other wastewater treatment process like gravity sedimentation i.e. polishing pond
treatment, fluctuation in the influent flow rate disturbs solid settling process and reduces
treatment unit effectiveness. Therefore, equalization of wastewater flow rate through a
wastewater treatment unit is very important for overall performance of the unit.

The equalization of flow prevents surges i.e. short term, high volumes of
incoming flow and controls the flow through each stage of the treatment system, allowing
adequate time for the physical, biological and chemical processes to take place.
Equalization unit consists of large tanks or basins where a certain percentage of daily
wastewater streams is held to stabilize flow turbulence and is then discharged at a
constant flow rate to downstream treatment units.
Advantage:
•

Flow equalization eliminates or at least minimizes shock loadings throughout the
downstream of wastewater treatment processes, thereby enhances performance of
those treatment processes.

•

Flow equalization prevents system overloading.

•

Equalization tanks consolidate smaller volumes of wastewater streams so that, for
batch treatment systems, full batch volumes are available.

Limitations:
•

Flow equalization unit requires large land areas which increases capital cost.

•

Additional operational cost may be required for odor control.
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3. Advanced Biological Treatment:
Advanced biological treatment is a very useful method of degrading various organic
constituents in pharmaceutical wastewater and hence, is widely used in pharmaceutical
manufacturing industries to treat BOD5, COD, and TSS of wastewater stream. In fact, by
using this method, BOD5 and COD of wastewater stream can be reduced by 90% and
75% respectively, in respect of their values in untreated wastewater. (USEPA Technical
Development Document. 1998, 7-11)

Biological treatment of wastewater can be carried out either in presence of oxygen which
is also called aerobic treatment or in absence of oxygen which is also called as anaerobic
treatment. Again, under the aerobic biological treatment methods, different technologies
are available like activated sludge process, surface impoundments, trickling filters,
rotating biological contractors (RBC), sequencing batch reactors (SBR) and others, out of
which, only first four methods are in common use in pharmaceutical manufacturing
industries. Among these four methods, the basic mechanism of activated sludge process
and surface impoundment process is the suspended growth technique in which
microorganisms are kept suspended within the liquid being treated and thus, allowed to
come into contact with the suspended and dissolved organic and nonmetallic inorganic
wastes. The basic mechanism of trickling filter and rotating biological contactors is the
fixed-film technique in which microorganisms are allowed to grow on a supporting
medium and form a biological slime layer and as the wastewater passes through the unit,
suspended and dissolved organic and nonmetallic wastes come in contact with the slime
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layer and decompose into carbon dioxide, water, nitrate, sulfate, organic byproducts and
cellular biomass. In both suspended growth and fixed film techniques, oxygen, nitrogen
and phosphorous are supplied to maintain the microbial load in the units. (Guyer, H.
1998; 151-6)

The essential parts of an activated sludge treatment system are an equalization
basin, a primary clarifier, an aeration basin, a secondary clarifier, and a sludge recycle
line. Prior to aeration step, settleable solids are removed in a settling tank which acts as
primary clarifier. Oxygen, recycled sludge, and nutrients are added to the aeration basin
to maintain the microorganism population. Microorganisms are kept suspended in the
aeration basin by the flow of oxygen, supplied by aerators. The secondary clarifier is
necessary to control the amount of suspended solids to be discharged and the sludge is
also obtained from this clarifier for recirculating to the aerated basin. For optimum
performance of the activated sludge system, equalization of flow, pH, temperature, and
pollutant loads is very important. (USEPA Technical Development Document.1998, 712)
Biological waste products and expired microorganisms are the primary
constituents of the generated sludge which is further treated to reduce overall volume
prior to disposal. The commonly used treatment methods are sludge thickening and
sludge dewatering. Gravity separation, dissolved air flotation, or centrifugation technique
is used for sludge thickening and filtration techniques like filter press, vacuum filter etc.
is used for sludge dewatering. Nutrient-to-microorganism ratio, sludge production rate,
percent BOD5 of effluent TSS, sludge retention time etc. are the some important
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parameter of activated sludge treatment system. Advanced biological treatment method,
when combined with nitrification, is also useful to reduce ammonia content of the
wastewater. This can be achieved by incorporating two sets of autotrophic 18
microorganisms in biological treatment units. One set of microorganisms i.e.
Nitrosomonas bacteria, converts ammonia to nitrites while the other one i.e. Nitrobacter
bacteria, converts nitrites to nitrates. Nitrification capability can be determined through
biological monitoring of both of the ammonia oxidizing bacteria and nitrite oxidizing
bacteria. It also can be determined by analyzing the nitrogen balance between the amount
of ammonia and that of the nitrite and nitrate (USEPA Technical Development
Document. 1998, 7-13).
Advantage:
•

Activated sludge process produce a very clean effluent within a reasonable period
of time.

•

Activated sludge process is not usually affected by external temperature
conditions.

•

Surface impoundment process is the cheapest method of organic waste treatment.

•

Potentially toxic chemicals can be treated biologically by surface impoundment
process as the toxic chemicals get diluted due to large volume of the treatment
unit.

•

Wastewater streams containing large variations of content can be effectively
treated by Sequential batch reactor (SBR).

18

Autotrophic microorganism - An organism that makes its own food (as in plants)
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•

Rotating biological contractor (RBC) can tolerate large surges in wastewater
concentrations.

•

Rotating biological contractor (RBC) requires low energy for operation.

Limitations:
•

Activated sludge process requires high amount of energy for operation.

•

Surface impoundment process is less effective during winter season as the process
is sensitive to temperature fluctuations.

•

Rotating biological contractor (RBC) requires high installation cost and high
operational cost. (Guyer, H. 1998; 153-6)

4. Cyanide Destruction
Cyanide compounds are highly toxic, not only to human beings but also to aquatic life as
they disturb their reproductive cycle and developmental stages. These compounds also
have neurotoxic effect. Thereby, removal of cyanide compounds or cyanide ions from
pharmaceutical wastewater is very important. Cyanide destruction methods are used for
this purpose. Cyanide destruction is a chemical treatment method by which cyanide is
converted to either inactive nitrogen gas or ammonia. Three chemical treatment methods
are widely used in pharmaceutical industries for cyanide destruction. These are alkaline
chlorination, hydrogen peroxide oxidation and basis hydrolysis method. All of these three
methods are batch operating methods. The choice of treatment method depends upon the
nature of cyanide compounds present in the wastewater stream.
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The alkaline chlorine treatment unit usually consists of two reaction vessels and
an equalization tank for storing of accumulated wastewater during treatment operation
(USEPA Technical Development Document.1998, 7-18). This reaction is a two step
process and is carried out separately in two reaction vessels. In the first step, sodium
hypochlorite reacts with cyanide ions of the wastewater stream and oxidizes cyanide to
cyanate ion (and also cyanogen chloride which is hydrolyzed to cyanate ion). In the
second step, this cyanate ion further oxidized by hypochlorite ion to nitrogen gas and
carbon dioxide. Temperature, pH and red-ox potential are important factors for the
effectiveness of this treatment process.

The hydrogen peroxide treatment unit usually consists of a reaction vessel,
hydrogen peroxide storage vessel, equalization tank, and feed systems for chemicals
(USEPA TDD.1998, 7-18). In the reaction vessel, hydrogen peroxide oxidizes the
cyanide ion to produce cyanate and water. The cyanate then hydrolyses over time
depending on the pH to give carbon dioxide and an ammonium salt or carbonate and
ammonia. To accelerate the reaction speed, sometimes copper sulfate is used as a
catalyst. Temperature and pH are important factors for the effectiveness of this treatment
process.

The basic hydrolysis treatment unit usually consists of a reaction vessel, storage
vessel and feed system for chemicals and heat exchanger (USEPA TDD.1998, 7-18). In
this process, cyanide ion reacts with water in presence of a base like sodium hydroxide

35

and produces formate and ammonia. Temperature and pH are important factors for the
effectiveness of this treatment process.

Advantages:
•

Alkaline chlorination process, in presence of heat, with an extended retention time
results in complete destruction of total cyanides of wastewater stream.

Limitations:
•

Alkaline chlorination process cannot effectively oxidize stable iron, copper, and
nickel cyanide complexes.

•

Hydrogen peroxide method requires high pH.

•

Hydrogen peroxide method is slow and requires copper catalyst to accelerate the
reaction rate.

•

Cyanide destruction processes involve high operational and maintenance cost.

5. Multi-media or Multi-layer Filtration
BOD5 content of wastewater is, in part, due its Total Suspended Solid (TSS) content and
this part of the total BOD5 content can be reduced by reducing the amount of particulate
matter of wastewater through filtration technologies. To reduce TSS in wastewater,
particularly multi-layer or multi-media filtration technology is used in pharmaceutical
industries. This method is also useful in dewatering of sludge. As the name implies, this
filtration unit is composed of a series of different types of filtering media. These typically
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consist of layers of activated charcoal, anthracite or hard coal, assorted rocks or gravels,
garnet or fine sand. Theses layers are arranged in descending order of their granule size
i.e. layer with the coarsest granular material is at the top of the filtering bed while the
finest granular material is at the bottom of the bed to facilitate the flow of wastewater
from inflow to outflow direction of the bed. The waste stream enters at the top of the
filter bed and as the wastewater percolates through the upper porous layers, the larger
suspended particles are trapped in and on to the upper porous layers of the bed. Smaller
particles, not trapped, continue into the lower layers of the bed. As the particle size in the
lower layers becomes smaller progressively, the space between the particles is reduced,
thereby trapping increasingly smaller suspended particles and thus increasing the capacity
of the filtration unit. As the wastewater passes through this filtering bed, suspended solids
are removed from the wastewater by any or a combination of straining, impaction,
sedimentation, interception and adsorption process. (Guyer, H. 1998; 72)

Multimedia filtration is a batch process and the filtration is continued until the
solids concentration increases to an unacceptable level in the effluent of the filtration
unit. Under such a condition, cleaning of the bed is done by backwashing of the filtering
media with a strong stream of clean water which is introduced at the bottom of the bed.
This process agitates or fluidized the filtering bed materials where the trapped solid
particulate matters get released from the bed and the concentrated wash water is pumped
off and is either returned to the biological treatment system or sent for further processing.
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Wastewater flow rate, hydraulic loading rate, and filter medium depth are the
important factors to be considered for effective operation of the multimedia filtration unit
(USEPA TDD. 1998, 7-15).
Advantages:
•

Multi-media filtration systems are able to filter a wastewater stream with a very
high amount of turbidity or suspended solids.

•

Multi-media filtration units filter wastewater streams at a much higher flow rate
than a single-media filtration unit.

•

Multi-media filtration units have a longer running time than a single media
filtration unit.

•

Multi-media filtration units require less backwash water per unit volume of
filtrate as the bed can hold more turbidity than that of a single media filtration unit
because suspended solids are trapped and held throughout the entire bed depth.

•

A very high degree of clarity is achieved because pore size of the filtration bed
decreases as the wastewater stream passes towards bottom of the bed. (Guyer, H.
1998; 73)

Limitations:
•

Multi-media filtration process involves high labor cost.

6. Polishing Pond Treatment
Sedimentation technology is also used in pharmaceutical industry to reduce TSS content
of wastewater stream. Polishing pond treatment process uses sedimentation technology
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where a wastewater stream that enters at one end point of the pond is allowed to remain
there for a pre-designated period of time, during which suspended solid (TSS) materials
settle to the bottom of the pond due to gravitational force and the supernatant wastewater
stream flows out the other end point of the pond (Guyer, H. 1998; 153-4). This process
also reduces some TSS associated BOD5 content of the wastewater stream due to removal
of TSS from the wastewater stream.

This is a batch process. The water retention time and wastewater stream velocity
are the important factors for the maximum effectiveness of this treatment technology
because these two factors should be set as such to allow maximum settling of TSS out of
the wastewater stream. The standard retention time is 14 to 15 days. The depth of the
polishing pond should be small to avoid anaerobic condition. The polishing pond usually
requires two liners and a leak detection system. (USEPA Technical Development
Document. 1998, 7-17)
Advantage:
•

Simple in operation.

Limitations:
•

Application of polishing pond is limited to wastewater stream containing
materials that are not restricted from land disposal.

•

Polishing pond treatment requires the use of large amount of land areas.
(Guyer, H. 1998; 153-4)
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7. Steam stripping and steam stripping with rectification
Another important wastewater treatment technology in pharmaceutical manufacturing
industries is steam stripping and/or steam stripping with rectification. This method works
on the basic principle of relative volatility differences between organic chemicals and/or
inorganic gases like ammonia, and water, thereby separates organic chemicals and/or
ammonia from wastewater stream as it passes through the unit. This method is very
useful in treating a variety of wastewater streams, containing a single to a complex
mixture of the volatile constituents. The unit is installed immediately after the wastewater
generating unit for maximum effectiveness of the treatment operation.
Steam stripping and steam stripping with rectification can be conducted as
either a batch or continuous operation in a packed tower or fractionating column
(sieve tray or bubble cap) with more than one stage of vapor-liquid contact. In a
steam stripping column, the wastewater feed enters near the top of the column and
then flows downward by gravity, countercurrent to the steam which is introduced
at the bottom of the column. In a steam stripping with rectification column, the
wastewater feed enters lower down the column to allow for a rectification above
the feed. In the rectification section, a portion of the condensed vapors are
refluxed to the column to counter currently contact the rising vapors. This process
concentrates the volatile components in the overhead stream.

Steam may either be directly injected or re-boiled, although direct
injection is more common. The steam strips volatile pollutants from the
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wastewater, which are then included in the upward vapor flow. As a result, the
wastewater contains progressively lower concentrations of volatile compounds as
it moves toward the bottom of the column. The extent of separation is governed
by physical properties of the volatile pollutants being stripped, the temperature
and pressure at which the column is operated, and the arrangement and type of
equipment used.

The difference between steam stripping columns and steam stripping with
rectification columns is the location of the feed stream. Stripping columns have a
feed stream located near the top of the column while steams stripping with
rectification columns have a feed stream located further down the column.
Pollutants that phase separate from water can usually be stripped from the
wastewater in a steam stripper (a column without rectifying stages). Pollutants
that are not phase-separable, such as methanol, need a column with rectifying
stages to achieve a high concentration of the pollutants in the overhead stream.

The typical construction material for steam stripping and steam stripping
with rectification columns in the pharmaceutical manufacturing industry is
stainless steel. If a wastewater stream is highly corrosive, a more corrosionresistant material, such as Hastelloy or Teflon®-lined carbon steel, may be
required for construction of the column. The majority of pharmaceutical
manufacturing facilities which currently use steam stripping and/or steam
stripping with rectification columns to treat their wastewater use stainless steel.
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Salts and other pollutants may contribute to scaling and corrosion inside the
column. Timely maintenance should be provided to deter scaling problems.
Generally, columns with smaller diameters are packed while columns with larger
diameters have trays. Typical column packings are Pall rings, Rashing rings, Berl
saddles, and Intalox saddles. The key design parameters for stripping columns are
the steam-to-feed ratio and the number of trays or equilibrium stages in packed
columns. These parameters are calculated using the equilibrium ratio of the least
strippable contaminant in the wastewater stream and the removal efficiency
required to treat the contaminant to the desired concentration. Typical ranges for
steam-to-feed ratios vary from 1:3 to 1:35, and the typical number of trays or
equilibrium stages vary from 2 to 20 (USEPA Technical Development
Document.1998, 7-19; 21).
Advantages:
•

The main advantage of stream stripping is that, unlike air stripping, resultant offgas stream is usually condensed and the contained constituents is recovered or
incinerated.

•

Steam stripping removes both volatile organic and volatile inorganic constituents
of wastewater stream.

Limitations:
•

Steam stripping is operated at higher temperatures and some times results in heat
stress in the surrounding environment.

•

Steam stripping process involves high operational and maintenance cost.
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8. Granular Activated Carbon Adsorption
Adsorption is one of the surfaces phenomenon by which dissolved or suspended materials
can be removed from a gas or a liquid stream through bond formation with the bonding
sites of a solid adsorbent surface. Different types of adsorbents like, activated carbon,
silica gel, alumina etc. are available for this purpose but, granular activated carbon is
considered the best among all of these adsorbents due to its hydrophobic nature, high
internal surface area and high surface bonding affinity to most of the other compounds.
Therefore, granular activated carbon adsorption method is widely used to reduce BOD5,
COD and organic constituents of pharmaceutical wastewater.

Activated carbon is prepared by destructive distillation of carbon containing
materials like coconut shell, wood etc and then either it is powdered or broken down to
granule size to increase its internal surface area.

In wastewater treatment unit, either activated carbon is packed into columns or
bed of activated carbon is prepared into large enclosed tanks. Enclosed tanks are more
common in wastewater treatment and more than one tank is use in series to ensure
maximum effectiveness of the treatment process. When wastewater passes through these
columns or tanks, its constituents come in contact with the surface of activated carbon
and get adsorbed on to the surface of the activated carbon due to bond formation with the
surface bonding sites. As the time goes on, the surface area of the upper layer of activated
carbon bed becomes saturated and consequently, the adsorption zone moves downward to
the lower level. This process continues until almost all of the activated carbon in the bed
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becomes saturated and the constituents of wastewater, being treated, appear in the
effluent of treatment unit at a higher value than the acceptable limit. At this point, the
activated carbon is called spent. This spent activated carbon can be regenerated by
destructive distillation or by backwashing with steam or by chemical treatment. After a
few cycle of regeneration, adsorbing capacity of the activated carbon goes down below
the acceptable level and then it is disposed off. (Guyer, H. 1998; 88-89)

The effectiveness of wastewater treatment by granular activated carbon
adsorption process depends on three important factors. These are wastewater TSS
concentration, saturation loading and hydraulic loading. (USEPA Technical Development
Document.1998, 7-24)
Advantages:
•

Low space is required for GAC.

•

One major advantage of Granular Activated Carbon technology is its ability to
remove a wide variety of toxic organic compounds to non-detectable level
(99.99%)

•

Low operational and maintenance cost.

Limitations:
•

GAC unit works best at low suspended solids concentration of wastewater.

•

Bacterial growth in granular carbon beds generates hydrogen sulfide which
creates odors and corrosion problems.

•

GAC adsorption is highly sensitive to pH, temperature, and flow rate of
wastewater.
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•

Wet spent carbon from GAC unit is highly corrosive and abrasive creates land
disposal problem. (EPA Wasterwater Technology Fact Sheet, Sept. 2000)

9. Air Stripping
Air stripping technology is very useful in removing volatile organic compounds (VOCs)
as well as volatile inorganic compounds like ammonia, from pharmaceutical wastewater
stream. Air stripping is carried out either in a countercurrent, packed column or in an
aeration tank. In these treatment units, wastewater is sprayed by a spray nozzle at the top
of the unit. As the wastewater descends through the treatment unit, air is forced upward
through the unit, stripping off the volatile compounds and then the volatile compounds
are carried out of the system at the top of the unit with air stream. Internal baffles inside
the treatment unit increase surface area of the wastewater and thereby, increase
wastewater-air contact and thus maximize volatilization of volatile compounds from
wastewater. Effluent of these treatment units is discharged at the bottom of the units.
(USEPA Technical Development Document. 1998, 7-28)
Advantages:
•

Air stripping removes both volatile organic and volatile inorganic constituents of
wastewater stream.

•

Air stripping is a cost-effective method of wastewater treatment.
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Limitations:
•

It removes volatile contaminants from wastewater stream but, discharges the same
contaminants into the surrounding atmosphere.

•

At low temperature, air stripping is less efficient and there is a possibility of
freezing within the tower. (USEPA Technical Development Document.1998, 728)

10. Incineration
Incineration is used in pharmaceutical industries where diverse toxic or very toxic
wastewater streams are produced due to chemical multi-products production operations
and these wastewater streams cannot be routed to a conventional wastewater treatment
plant. Different types of incinerators are available for this purpose like rotary-kiln,
fluidized bed, multiple/stepped hearth etc. Among this, fluidized bed and multiple hearth
incinerators are more common in pharmaceutical industries. An acid gas scrubber is used
to control Hydrochloric acid that is generated during incineration. In this process, organic
and inorganic contaminants of wastewater are thermally destroyed to ash and the
resultant water vapor is discharged to air. (USEPA Technical Development
Document.1998, 7-29)
Advantage:
•

Incineration is the most effective way of complete destruction of all contaminants
of wastewater stream.
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•

Complete incineration destroys chemical properties of hazardous wastes.

Limitations:
•

High working temperature creates thermal stress in the surrounding environment.

Product Stewardship
Product stewardship is a broad term and is a product-centered concept of reducing
environmental impacts of a product throughout its life cycle, through shared
responsibility of manufacturer, retailers, users and disposers. As per EPA –
In most cases, manufacturers have the greatest ability, and therefore the greatest
responsibility, to reduce the environmental impacts of their products. Companies
that are accepting the challenge are recognizing that product stewardship also
represents a substantial business opportunity. By rethinking their products, their
relationships with the supply chain, and the ultimate customer, some
manufacturers are dramatically increasing their productivity, reducing costs,
fostering product and market innovation, and providing customers with more
value at less environmental impact. Reducing use of toxic substances, designing
for reuse and recyclability, and creating take-back programs are just a few of the
many opportunities for companies to become better environmental stewards of
their products. (EPA Product Stewardship, July 2007)

To address the issues of pharmaceuticals and other personal care products in the
environment, pharmaceutical manufacturers should have to take on new responsibility for
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reducing the environmental impacts of their products. Currently, pharmaceutical
manufacturers are exercising different product stewardship programs like formulation
alteration or modification, pharmaceuticals mail-back program, pharmacy take-back
program etc. In fact, all of these product stewardship programs are proactive approaches
to address the PPCPs issues. All these approaches are very important as majority of this
PPCPs issue is due to fecal excretion of non-metabolized or incomplete metabolized
portion of drug formulations, improper method of disposal of unused prescription and
non-prescription drugs or personal care products present in household wastewater.

Formulation alteration or modification
When a drug is administered through any of the local routes (like gastrointestinal tract,
vagina, bronchi, eye, ear etc.) or systemic routes (like parenteral, rectal, sublingual etc),
it undergoes four basic processes within the body. These are absorption, distribution,
metabolism and excretion. That means, drug is absorbed first into the blood or lymphatic
system, then is generally distributed to target organ(s) and produce desired effect(s); then
goes to liver and metabolized there to inactive form(s) and finally, excreted through
kidney. Exception is there, like some drugs after absorption into the system, first go to the
liver and metabolized to more reactive form(s) and then go to the target organ(s) to
produce the desired effect(s). However, all of theses four processes are very important
consideration for product stewardship approaches because disturbance in any of these
processes or incompleteness of any of theses processes results in excretion of active
constituent(s) of drug formulation(s) into the environment.
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If drugs are not completely absorbed into the system then non-absorbed portion
excretes as such from the body; if the absorbed portion is not completely metabolized
inside the body then the non-metabolized portion of the active constituents excrete as
such into the environment; some time metabolized portions that excrete through kidney is
more toxic in nature that the parent compounds. If drugs are not distributed properly into
the system then it results in incomplete metabolism and excretion of active constituents
from the body. Therefore, pharmaceutical industries are working on drug formulations
for alteration or modification of formulations and/or modification of chemical structure
of active constituents of drug, to increase drug absorption, to increase drug metabolism,
to increase drug distribution and their target is to achieve 100% in all of drug absorption,
distribution, metabolism processes to ensure that drug constituents are being excreted into
the environment in least possible amount in their biologically most inactive form(s).

Digoxin is used in cardiac disease like cardiac arrhythmia, ischemic heart disease
etc. When Digoxin is administered orally, ~70% is absorbed into the blood, of which
25% bounds to plasma proteins and transported to and localized in heart, skeletal muscle,
liver and kidney; a small fraction is metabolized in liver to inactive products and is
primarily excreted unchanged by glomerular filtration in kidney, has a total body
clearance of ~ 150mL/min and a plasma half life (t1/2) of ~ 40 hours. Therefore, each
single tablet of digoxin contributes active constituent to the environment to some extent
through human fecal excretion. Moreover, the total amount of digoxin in each tablet
should be the sum of the amount required to achieve the minimum effective
concentration (MEC) in blood and the amount that is excreted unchanged from the body.
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Therefore, this incomplete absorption and/or incomplete distribution and/or metabolism
of drug not only gives rise to PPCPs issue but also, causing destruction of natural
resources (as the active constituent of digoxin tablet is digitalis glycoside which is
extracted from digitalis plants) and at the same time, increases the drug price in the
market. So, modification of digoxin tablet formulation or modification of digitalis
glycoside structure could enhance lipoprotein solubility of the active constituent, thereby
increases drug absorption; similarly, it could increase drug-protein binding and thereby,
increases drug distribution and drug-receptor binding at the target site(s). Therefore, less
amount of drug will be required to incorporate into the dosage form to get the same effect
while excretion of active constituent into the environment will be less. In this way,
product stewardship could help to solve all of the above mentioned issues. Under certain
condition or disease state like vomiting, there is incomplete absorption of drugs that
results in discharge of active constituents into the environment. This is not controllable
through product stewardship.

Pharmacy take-back program
Another major source of PPCPs in the environment is improper household disposal of
expired or unwanted prescription or Over-The-Counter (OTC) drugs by flushing them
down the toilet or drain. Although it is an improper method of disposal of drugs
containing different bio-reactive constituents but, it has become a traditional method and
is widely being used now-a-days.
The best method of disposal of household expired or unwanted prescription or
Over-The-Counter (OTC) drugs is to return these medications to nearby pharmacies,
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through pharmacy take-back program, for destruction. As per Daughton (The Green
Pharmacy, 2003) –
It is designed to accept the free return of all prescription and OTC medications
(and certain other medically oriented products); it does not, however, accept
physician samples.

Besides local pharmacies, now-a-days pharmaceutical industries also have been
started to participate in this program to collect both pharmacies’ own in-stock expired
drugs and that collected by these pharmacies from consumers through pharmacy takeback program, and to destroy these drugs in a proper manner.

Pharmaceuticals mail-back program
This is similar to pharmacy take-back program with the exception that under this
program, instead of returning back to pharmacies, consumers are able to free return of
their expired or unwanted prescription or Over-The-Counter (OTC) drugs directly to the
participating pharmaceutical industries by postal mail services.
The drawback of this program is that the postage requirements for mailing back
the drugs discourage people to participate in the program.

51

II. Case Studies
The websites of the following pharmaceutical companies have been visited to identify
their respective approaches toward PPCPs in the environment.
1. 3M Pharmaceuticals
2. Abbott Laboratories
3. Albert David Ltd
4. AstaZeneca International
5. Bristol Mayer Squibb
6. GlaxoSmithKline
7. Patheon, Inc.
8. Pfizer
9. Sandoz
10. Wyeth Pharmaceuticals

The different approaches that the pharmaceutical industries are using to address the issues
of PPCPs, have been given in the following table:
Table 5
Number of
Industries Using
this Approach
10
8

Approaches
End-of-Pipe Wastewater Treatment
Product Stewardship
Combination of both the above

8
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Total
Percentage
(%)
100
80
80

The different technologies that the pharmaceutical industries are using have been given in
the following table (this information has been collected both from case studies and
interview):
Table 6

Technology
pH adjustment or Neutralization
Equalization
Advanced
With Nitrification
Biological
Without Nitrification
Treatment
Alkaline Chlorination
Cyanide
Hydrogen Peroxide Oxidation
Destruction
Basic Hydrolysis
Multi-Media Filtration
Polishing Pond
With Rectification
Steam Stripping
Without Rectification
Granular Activated Carbon Absorption
Air Stripping
Incineration
Formulation Modification
Structural Modification
Product
Stewardship
Pharmacy Take-Back
Pharmaceutical Mail-Back

Number of
Industry Using
This
Technology
10
8

Total
Percentage
(%)
100
80

6

60

3
1
1
0
6
1
0
1
7
3
2
8
6
2
1

30
10
10
00
60
10
00
10
70
30
20
80
60
20
10

The total number in the first column is greater than 10 and the total of the percentage in
the second column is greater than 100 because some of those industries use more than
one treatment technologies.

All of the industries that use either fermentation or chemical synthesis or both are
using at least Advanced Biological Treatment technologies; some of them are using a
combination of Advanced Biological Treatment and Effluent Filtration or Advanced
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Biological Treatment and Polishing Pond, while the rest is using a combination of
Advanced Biological Treatment and Effluent Filtration and Polishing Pond. All other
industries that use either biological/natural extraction or mixing-compoundingformulating or both are using at least Advanced Biological Treatment technologies; some
of them are using a combination of Advanced Biological Treatment and Effluent
Filtration.

Bristol-Myers Squibb (Sermoneta, Italy) is using a system comprised of an
advanced biological reactor with nitrification/denitrification combined with advanced
ozone oxidation as a part of their wastewater treatment approaches while Pfizer
(Ringaskiddy, Ireland), the GlaxoSmithKline (Carrigaline, Ireland) and Abbott
Pharmaceuticals (Puerto Rico) are using ZeeWeed membrane bioreactors for reliable and
effective treatment of wastewater, avoiding some problems experienced with
conventional settlement technology. Wyeth Pharmaceuticals (Newbridge, Scotland) is
using a combination of membrane bioreactor and ozone treatment system to treat
wastewater stream onsite. AstraZeneca also treats many of its wastewater streams using
onsite biological treatment units. 3M Pharmaceuticals and Sandoz (New York) use
filtration technology as a main part of their wastewater treatment while Patheon, Inc.
(Whitby, Canada) use a combination of Steam Stripping and onsite biological treatment
unit to treat their wastewater stream. Albert David Ltd. use cyanide destruction and air
stripping system in combination with onsite biological treatment system to treat
wastewater treatment. Albert David Ltd. also uses onsite polishing pond to treat their
wastewater streams.
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Most of these 10 industries are also using product stewardship approaches. The
specific product stewardship programs are formulation modification, structural alteration,
pharmacy take-back program and pharmaceuticals mail-back program. Formulation
modification is the most common program that industries are using to reduce
environmental impacts of their products while some industries are concentrating on
pharmacokinetic properties of drug molecules and are trying to reduce environmental
impacts of their products through structural modification of the active ingredients. A very
few of them have participated in pharmacy take-back program and one of them has
started pharmaceutical mail back program as a part of their product stewardship
approaches.

III. Interviews:
According to responses to the Detailed Questionnaire of the interviews:
∗

All of the ten pharmaceutical manufacturing facilities reported using pH
adjustment or neutralization treatment of their wastewater stream as a
pretreatment, prior to other physical, chemical and biological wastewater
treatment processes to improve their effectiveness. Advanced biological
treatment process is highly pH sensitive and so, pH adjustment is necessary
before advanced biological treatment of wastewater. Also pH plays an important
role in solubility of many wastewater contaminants and pH adjustment helps to
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remove these contaminants through precipitation. However, this is a chemical
addition process and different neutralizing chemicals are added during the
process that increases total chemical load. CaO, Ca(OH)2, NaOH etc. are usually
used to raise pH while HCL, SO2 gas, H2SO4 etc. are normally used to lower pH
of the wastewater stream. Some facilities are using liquefied CO2 in place of
H2SO4. NaOH is expensive and CaO is very cheap and easily available.
Therefore, CaO is the most preferred agent for treating acidic wastewater
stream. Eight of the ten pharmaceutical manufacturing facilities reported using
flow equalization unit to consolidate smaller volumes of wastewater streams so
that, for batch treatment systems, full batch volumes are available and at the
same time, to eliminate or at least to minimize shock loadings throughout the
downstream of wastewater treatment processes to prevent system overloading.

∗

Nine of the ten pharmaceutical manufacturing facilities reported using advanced
biological treatment unit to remove organic and inorganic contaminants of their
wastewater stream. Activated sludge is the most preferred process as it produces
a very clean effluent within a reasonable period of time and not affected by
external temperature conditions. Although surface impoundment is the cheapest
method and can tolerate a large amount of potentially toxic chemicals, it is not
preferred due to large amount of expensive land space requirement. Sequential
batch reactor (SBR) and Rotating biological contractor (RBC) are not preferred
due to high installation and high operational costs. Now-a-days, many industries
are preferring membrane bioreactor technology for reliable and effective
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treatment of wastewater, avoiding some problems experienced with
conventional activated sludge process. Bristol Mayer Squibb (Sermoneta) is
using a system comprised of an advanced biological reactor with
nitrification/denitrification combined with advanced ozone oxidation to reduce
hard COD. The GlaxoSmithKline (Carrigaline) is using a system consists of an
equalization tank, pretreatment screening, a combination bioreactor and
filtration tank equipped with fine bubble diffused aeration for aerobic biological
treatment and ZeeWeed UF membranes. As per Mr. Simon of GlaxoSmithKline
– “We use MBR technology as it offers a proven alternative to conventional
approaches to the treatment of PWW, which poses particular problems for
conventional treatment technology due to variations in feed-water strength and
potential shock loading, and high dissolved solids content leading to floc
destabilization and subsequent biomass leakage, resulting in a deterioration in
treated effluent quality. Moreover, this generates an effluent permeate of
consistently high quality, superior in performance to CAS alternatives. This
MBR technology has proved valuable in achieving reliable and cost-effective
treatment for our global pharmaceutical industry.” Pfizer (Ringaskiddy) is using
membrane bioreactor technology effectively overcomes the problems associated
with poor settling of sludge in conventional activated sludge processes. Abbott
Pharmaceuticals (Puerto Rico) is using membrane bioreactors as MBR process
combines the unit operations of aeration, secondary clarification and filtration
into a single process, producing a high quality effluent, simplifying operation
and greatly reducing space requirements.
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∗

Two of the ten pharmaceutical manufacturing facilities reported using cyanide
destruction process to remove cyanide compounds or cyanide ions from their
wastewater stream. Alkaline chlorination is the most preferred process as within
an extended retention time and in presence of heat, it results in complete
destruction of total cyanides of wastewater stream. Hydrogen peroxide method
is not preferred as it requires high pH and reaction rate is slow, requires copper
catalyst to accelerate the reaction rate and copper recovery increases operational
cost.

∗

Six of the ten pharmaceutical manufacturing facilities reported using multimedia filtration system as it is able to filter wastewater stream with a very high
amount of turbidity or suspended solids and a very high degree of clarity is
achieved because pore size of the filtration bed decreases as the wastewater
stream passes towards bottom of the bed. It is preferred over single media
filtration system as it filters wastewater stream at a much higher flow rate and
has a longer running time than a single media filtration unit. As per Mr. Bill N.
of 3M Corporate Communication – “We use a number of different technologies
depending on the facility. The most common technology for treating waste
water at 3M is a filter technology.”

∗

One of the ten pharmaceutical manufacturing facilities reported using polishing
pond to remove suspended solids from their wastewater stream. Although the
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operation is very simple but, polishing pond is not preferred due to large amount
of expensive land space requirement.

∗

One of the ten pharmaceutical manufacturing facilities have been reported using
stream stripping process to remove volatile contaminant of their wastewater
stream. This process is preferred over air stripping in that, unlike air stripping,
resultant off-gas stream is usually condensed and the contained constituents is
recovered or incinerated.

∗

Seven of the ten pharmaceutical manufacturing facilities reported using granular
activated carbon adsorption to remove dissolved or suspended organic and
inorganic contaminant of their wastewater stream. It is a highly preferred
process of wastewater treatment due to its low space requirements and low
operational and maintenance cost requirements.

∗

Two of the ten pharmaceutical manufacturing facilities have been reported using
incineration process for complete destruction of all contaminants of wastewater
stream and 3 of the 10 pharmaceutical manufacturing facilities have been
reported using air stripping to remove volatile organic and inorganic
contaminant of their wastewater stream. Although air stripping is a costeffective method but is not preferred as it discharges volatile contaminants into
the surrounding atmosphere.
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∗

Eight of the ten pharmaceutical manufacturing facilities have been reported
being involved with different product stewardship programs. All of them, who
have participated in product stewardship, are doing research on formulation
modification or alteration in order to substitute eco-toxic ingredients like
different additives in dosage forms i.e. binding agent, dissolution agent,
disintegrating agent, preservatives, emulsifying agents etc. from their
formulations with biologically inert substances or eliminate these at all. 6 out of
these 8 industries are involved in research on structural modification of drug
molecules in order to improve pharmacokinetic properties of those molecules,
thereby ensuring more effectiveness of the drugs and less fecal excretion into the
environment. Two of these eight industries have participated in pharmacy takeback program to assist pharmacies in proper disposal of the expired or partially
used prescription and non-prescription drugs, collected from local residents. One
of these industries has also started pharmaceutical mail-back program to collect
expired or partially used prescription and non-prescription drugs directly from
the customer and dispose the same in an environmentally friendly manner. As
per Mr. Simon of GlaxoSmithKline “We have voluntarily started to collect
unwanted medicines from customers through pharmacy take back program and
pharmaceuticals mail back program to make sure that drugs are not being
disposed in an improper manner by the customers. In near future, we have a plan
to recover active ingredients from these unused medicines to reduce our overall
production costs”.
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IV. Analysis:
From both the case studies and interview, it has been found that all
pharmaceutical industries are involved in onsite wastewater treatment operation to some
extent. They do pH adjustment and filtration at minimum. The wastewater treatment
technologies vary from unit to unit according to the type of chemical used and the type of
pharmaceutical manufacturing process in place. As the wastewater treatment technologies
are chemical specific or process specific, therefore the question of determining the best
treatment technology is not relevant here.

All of the pharmaceutical industries, contacted for the purpose of this research,
believe that product stewardship is the best approaches to address the issue of PPCPs on a
long term basis. Product stewardship is not economically feasible in all the cases and
end-of-pipe wastewater treatment is the best option there. However, two of these ten
pharmaceutical industries who are not currently involved in any of the product
stewardship approaches, have a plan to become actively involved in near future, in
addition to their end-of-pipe wastewater treatment activities because all the
pharmaceutical industries believe that neither end-of-pipe wastewater treatment activities
nor the product stewardship approaches could alone address the issues of PPCPs in the
environment; but that a combination of these two approaches could address the issues
more effectively.
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Conclusion:
Proactive approach, if economically feasible, is always preferred over reactive approach
as it provides a long term solution to the problem. Moreover, proactive approach gives
more economic benefit on a long-term run than that of reactive approach. The same
concept is also true in case of addressing the issues of PPCPs in the environment. In this
case, proactive approach like different product stewardship methods is considered better
than reactive approach like different wastewater treatment methods. However, none of
these two approaches could alone address the issues of PPCPs in the environment; rather
a combination of different product stewardship approaches with some kind of wastewater
treatment methods could address the issues more effectively.

As the major sources of PPCPs in the environment are human excreta and
improper disposal of unwanted medicine, different product stewardship approaches have
been proved very effective in addressing the issues. Besides formulation modification and
structural modification of drug components, pharmacy take-back program could also play
a major role in addressing the issues but, lack of incentive resists people from
participating into this program. In fact, expired or unwanted medicines in acceptable
condition (i.e. such a physical condition of the formulation that does not show any sign of
contamination or deterioration or any other kind of changes) could be collected either
through pharmacy take-back program or through pharmaceuticals mail-back program
from customers for the purpose of recovering active ingredients of drug formulation,
thereby saving the cost of expensive active ingredients for the next batch(s) of medicine
which, in turn, could allow the Pharmaceutical companies to provide some incentive, in
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the form of price discount, to their customers to encourage them to participate more and
more in Product Stewardship programs. This concept has been praised by Mr. Simon of
GlaxoSmithKline and he also believes that this concept could be proved beneficial to
Pharmaceutical Companies.

For the purpose of this paper, a few of the renowned pharmacies like CVS
pharmacy, Rite Aid pharmacy, Duane Reade pharmacy and Sunnyside Pharmacy have
been contacted and as per their statistics, only 2% of their total customers (assuming that
50% of total customers have unwanted medicines) have participated in pharmacy takeback program. The pharmacy personnel believe that this percentage could be increased
by providing some kind of incentives to the participants and particularly, the Sunnyside
pharmacy likes the concept mentioned in the above paragraph because that concept could
help pharmacies to provide 1-2% discount to the participants on the price of their next
purchase of the similar category of drugs which could act as an incentive and would
encourage people to participate more and more into the product stewardship program.
Therefore, how this concept will work? People return unwanted i.e. expired medicines to
the pharmacies. Expired medicine does not mean that it has reduced efficacy or no
efficacy, rather in most of the cases, it has full efficacy as unexpired medicine. In fact,
pharmaceutical manufacturers set this expiry date as 1/10th of the actual shelf life of the
formulation to avoid any deformity in the formulation like color change, phase separation
etc. Therefore, pharmaceutical manufacturer could collect these expired medicines in
acceptable condition from consumers through pharmacies and could extract the active
ingredients of those formulations and also could use these active ingredients in the
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manufacture of fresh batches of medicines. In this way, pharmaceutical manufacturer
could save the cost of active ingredients of formulations (if the extraction cost is less than
the cost of procuring active ingredients from other sources) which could, in turn, allow
them to provide discount to the participating customers on the price of their next purchase
of the similar category of drugs. As for example, if a customer returns an antimicrobial
drug of quinolones group to a participating pharmacy, the pharmacy will issue a discount
coupon to that customer and upon producing this coupon to a participating pharmacy, the
customer will get a discount on the price of their next purchase of any quinolones group
of antimicrobial preparation. This discount money will inspire more people to participate
in the pharmacy take-back program. In this way, pharmaceutical industries could also
actively participate in the pharmacy take-back program and both, pharmaceutical
industries and their ultimate consumer could be benefited and at the same time, problem
of improper household disposal of unwanted medicine could be solved. In the similar
way, pharmaceutical mail-back program could also be very effective in addressing the
issues of PPCPs in the environment.

Regarding participation issue related to pharmacies, there is no legislation till to
date for pharmacies to participate in pharmacy take back program; rather the approach is
totally voluntary, but it can be hoped, this would become legislation in the near future. In
addition to all of the above mentioned approaches, educating people about the issues of
PPCPs is another very useful product stewardship approach that some pharmaceutical
companies and pharmacies have voluntarily started e.g. Sunnyside pharmacy distributes a
quarterly environmental awareness leaflets within the local community for fostering the

64

environmental awareness among the general public. If other pharmaceutical companies
and pharmacies come forward to take such a voluntary initiative, then dealing with the
issues of PPCPs would be much easier in future.
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Appendix A:

Detailed Interview Questionnaire

Company: __________________________
Name: _____________________________
Title: ______________________________
Department/Unit: ____________________
Date: ______________________________

•

What are the most recent approaches from company’s perspective to address this
issue?

•

Why they have chosen any particular approach?

•

Why they are not using any other approaches?

•

What onsite wastewater treatment technologies they are using? What is their
limitation(s)?

•

What they think about the best way to address the issue of PPCPs?

•

What they are thinking to do in near future regarding the issue of PPCPs?

•

Are they doing so actually to protect our environment, or just due to some
regulatory concern to look the company doing better?
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Appendix B:

Website of Pharmaceutical Industries Visited for Case Study Purpose:
3M Pharmaceuticals – www.3M.com
Abbott Laboratories – www.abbott.com
Albert David Ltd – www.albertdavidindia.com
AstaZeneca International – www.astazeneca.com
Bristol Mayer Squibb – www.bms.com
GlaxoSmithKline – www.gsk.com
Patheon, Inc. – www.patheon.com
Pfizer – www.pfizer.com
Sandoz – www.sandoz.com
Wyeth Pharmaceuticals – www.wyeth.com
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